Patients with indolent lymphomas are at high risk of infections: experience from a German outpatient clinic

BMC Immunology

Table 1 Demographics

		Patients		Control group
		Number	Mean	Number	Mean
Age		n = 227	68.8 years	n = 145	67.2 years

		Number	%	Number	%
Age groups	69 years or younger	n = 118	52.0	n = 74	51.0
Age groups	70 years or older	n = 109	48.0	n = 71	49.0
Sex	Female	n = 81	35.7	n = 51	35.2
Sex	Male	n = 146	64.3	n = 94	64.8
Hematological diagnosis	CLL	n = 76	33.5
	Follicular lymphoma	n = 50	22.0
	Multiple myeloma	n = 50	22.0
	Waldenstrom's disease	n = 20	8.8
	Hairy cell leukemia	n = 16	7.0
	Mantle cell lymphoma	n = 5	2.2
	Marginal zone lymphoma	n = 5	2.2
	Lymphoplasmocytic lymphoma	n = 3	1.3
	Small cell B-cell lymphoma	n = 1	0.4
	Multiple myeloma and CLL	n = 1	0.4
Systemic therapy	No systemic therapy	n = 50	22.0
	No systemic therapy during observation	n = 116	51.1
	Systemic therapy during observation	n = 61	26.9
IgG replacement	no IgG Replacement	n = 171	75.3
	no IgG Replacement during observation	n = 14	6.2
	IgG replacement during observation	n = 42	18.5
Patient groups	No immunodeficiency No IgG replacement	n = 105	46.3
	Non-symptomatic immunodeficiency No IgG replacement	n = 60	26.4
	Symptomatic immunodeficiency IgG replacement	n = 51	22.5
	Symptomatic immunodeficiency No IgG replacement	n = 6	2.6
	No or non-symptomatic immunodeficiency. IgG replacement	n = 5	2.2
Death during observation	Deceased	n = 4	1.8
Death during observation	Not deceased	n = 223	98.2
Cause of death	Comorbidity	n = 2	50.0
	Lymphoma	n = 1	25.0
	other	n = 1	25.0

ISSN: 1471-2172